New combo therapy tested for Hard-to-Treat leukemia
NCT ID NCT03578367
Summary
This study tested whether adding a new drug called asciminib to the standard treatment imatinib could help patients with chronic myeloid leukemia (CML) achieve a deeper level of disease control. It involved 104 adults whose CML was not fully controlled by imatinib alone. Participants were assigned to either continue imatinib, switch to another drug, or add asciminib to their imatinib to see which approach worked best.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgia Regents University
Augusta, Georgia, 30912, United States
-
Novartis Investigative Site
Vienna, 1140, Austria
-
Novartis Investigative Site
Montreal, Quebec, H1T 2M4, Canada
-
Novartis Investigative Site
Brno, 625 00, Czechia
-
Novartis Investigative Site
Copenhagen, DK-2100, Denmark
-
Novartis Investigative Site
Bordeaux, 33076, France
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Roma, RM, 00161, Italy
-
Novartis Investigative Site
Krakow, 31 531, Poland
-
Novartis Investigative Site
Warsaw, 00-791, Poland
-
Novartis Investigative Site
Wroclaw, 50 367, Poland
-
Novartis Investigative Site
Lisbon, 1099-023, Portugal
-
Novartis Investigative Site
Porto, 4200-072, Portugal
-
Novartis Investigative Site
Moscow, 125167, Russia
-
Novartis Investigative Site
Moscow, 125284, Russia
-
Novartis Investigative Site
Saint Petersburg, 191024, Russia
-
Novartis Investigative Site
Saint Petersburg, 197341, Russia
-
Novartis Investigative Site
Uijeongbu-si, Gyeonggi-do, 11759, South Korea
-
Novartis Investigative Site
Seoul, Seocho Gu, 06591, South Korea
-
Novartis Investigative Site
Seville, Andalusia, 41009, Spain
-
Novartis Investigative Site
Badalona, Catalonia, 08916, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Valencia, 46026, Spain
-
Novartis Investigative Site
Changhua, 50006, Taiwan
-
Novartis Investigative Site
Taoyuan District, 33305, Taiwan
-
Novartis Investigative Site
Liverpool, CH63 4JY, United Kingdom
-
Novartis Investigative Site
London, W12 0HS, United Kingdom
-
Novartis Investigative Site
Oxford, OX3 7LE, United Kingdom
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21205, United States
Conditions
Explore the condition pages connected to this study.